Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

被引：9

作者：

Vij, Ravi ^{[1
]}

Martin, Thomas G., III ^{[2
]}

Nathwani, Nitya ^{[3
]}

Fiala, Mark A. ^{[1
]}

Gao, Feng ^{[1
]}

Deol, Abhinav ^{[4
]}

Buadi, Francis K. ^{[5
]}

Kaufman, Jonathan L. ^{[6
]}

Hofmeister, Craig C. ^{[6
,7
]}

Gregory, Tara K.

Berdeja, Jesus G.

Chari, Ajai

Rosko, Ashley E. ^{[8
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Wayne State Univ, Detroit, MI USA

[5] Mayo Clin, Rochester, MN USA

[6] Emory Univ, Sch Med, Atlanta, GA USA

[7] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Sch Med, Atlanta, GA USA

[8] Colorado Blood Canc Inst, Denver, CO USA

来源：

关键词：

D O I：

10.1182/blood-2019-130644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

602

引用

页数：4